BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, Cipolla A, Fabbri C, Pezzoli A. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996;24:141-147. [PMID: 8907566 DOI: 10.1016/s0168-8278(96)80022-5] [Cited by in Crossref: 213] [Cited by in F6Publishing: 51] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Thiele M, Gluud LL, Fialla AD, Dahl EK, Krag A. Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses. PLoS One. 2014;9:e107177. [PMID: 25225801 DOI: 10.1371/journal.pone.0107177] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
2 Ryu DH, Lee YM, Park JM, Tak WY, Hong NS. Examining Liver Cancer Patients and a High-Risk Group in a Vulnerable Area: An Experience from the Ulleung Liver Cancer Prevention and Management Project. Int J Environ Res Public Health 2020;17:E7757. [PMID: 33114104 DOI: 10.3390/ijerph17217757] [Reference Citation Analysis]
3 Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138-148. [PMID: 18848939 DOI: 10.1053/j.gastro.2008.09.014.] [Reference Citation Analysis]
4 Tziomalos K. Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B. World J Hepatol. 2010;2:91-93. [PMID: 21160979 DOI: 10.4254/wjh.v2.i3.91] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
5 Mori Y, Tamai H, Shingaki N, Moribata K, Shiraki T, Deguchi H, Ueda K, Enomoto S, Magari H, Inoue I. Diffuse intrahepatic recurrence after percutaneous radiofrequency ablation for solitary and small hepatocellular carcinoma. Hepatol Int. 2009;3:509-515. [PMID: 19669252 DOI: 10.1007/s12072-009-9131-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
6 Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci. 2011;56:1853-1861. [PMID: 21374066 DOI: 10.1007/s10620-011-1621-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
7 Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, Komatsu T, Taguri M, Tanaka K. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med 2019;8:1054-65. [PMID: 30791221 DOI: 10.1002/cam4.1998] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
8 Shao ZJ, Xu DZ, Yan YP, Li JH, Zhang JX, Zhang ZY, Pan BR. Detection of anti-HAV antibody with dot immunogold filtration assay. World J Gastroenterol 2003;9:1508-11. [PMID: 12854152 DOI: 10.3748/wjg.v9.i7.1508] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
9 Festi D, Sandri L, Mazzella G, Roda E, Sacco T, Staniscia T, Capodicasa S, Vestito A, Colecchia A. Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol 2004;10:12-6. [PMID: 14695760 DOI: 10.3748/wjg.v10.i1.12] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
10 Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27. [PMID: 15907199 DOI: 10.1186/1477-7819-3-27] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 5.3] [Reference Citation Analysis]
11 Kim SU, Lee JH, Kim DY, Ahn SH, Jung KS, Choi EH, Park YN, Han KH, Chon CY, Park JY. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One. 2012;7:e36676. [PMID: 22574212 DOI: 10.1371/journal.pone.0036676] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 7.8] [Reference Citation Analysis]
12 Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006;12:7239-49. [PMID: 17143937 DOI: 10.3748/wjg.v12.i45.7239] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
13 Iida H, Osaki R, Fujimoto T, Maehira H, Mori H, Kitamura N, Andoh A, Tani M. Interval between hepatocellular carcinoma treatment and interferon-free direct-acting antiviral agents against hepatitis C is necessary to suppress tumor recurrence. Mol Clin Oncol 2019;11:99-105. [PMID: 31289685 DOI: 10.3892/mco.2019.1847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, Ishibashi H, Yamada G, Yokosuka O, Shiratori Y. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut. 2004;53:425-430. [PMID: 14960528 DOI: 10.1136/gut.2003.030353] [Cited by in Crossref: 119] [Cited by in F6Publishing: 106] [Article Influence: 7.0] [Reference Citation Analysis]
15 Brown JL. Interferon therapy reduces the risk for hepatocellular carcinoma. Gut. 2000;47:610-611. [PMID: 11034573 DOI: 10.1136/gut.47.5.610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
16 van Meer S, de Man RA, Siersema PD, van Erpecum KJ. Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies. World J Gastroenterol 2013;19:6744-56. [PMID: 24187450 DOI: 10.3748/wjg.v19.i40.6744] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
17 Borzio M, Trerè D, Borzio F, Ferrari AR, Bruno S, Roncalli M, Colloredo G, Leandro G, Oliveri F, Derenzini M. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Pathol. 1998;51:96-101. [PMID: 9713593 DOI: 10.1136/mp.51.2.96] [Cited by in Crossref: 62] [Cited by in F6Publishing: 46] [Article Influence: 2.7] [Reference Citation Analysis]
18 Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol 2013;48:681-8. [PMID: 23463401 DOI: 10.1007/s00535-013-0770-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
19 Kimer N, Dahl EK, Gluud LL, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2012;2:e001313. [PMID: 23089208 DOI: 10.1136/bmjopen-2012-001313] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
20 Kubo S, Nishiguchi S, Shuto T, Tanaka H, Tsukamoto T, Hirohashi K, Ikebe T, Wakasa K, Kuroki T, Kinoshita H. Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. Jpn J Cancer Res 1999;90:162-70. [PMID: 10189886 DOI: 10.1111/j.1349-7006.1999.tb00729.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.3] [Reference Citation Analysis]
21 Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD;  HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138-148. [PMID: 18848939 DOI: 10.1053/j.gastro.2008.09.014] [Cited by in Crossref: 401] [Cited by in F6Publishing: 354] [Article Influence: 30.8] [Reference Citation Analysis]
22 Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53:744-749. [PMID: 15082595 DOI: 10.1136/gut.2003.020263] [Cited by in Crossref: 315] [Cited by in F6Publishing: 273] [Article Influence: 18.5] [Reference Citation Analysis]
23 Takeda Y, Nakao K, Nakata K, Kawakami A, Ida H, Ichikawa T, Shigeno M, Kajiya Y, Hamasaki K, Kato Y, Eguchi K. Geranylgeraniol, an intermediate product in mevalonate pathway, induces apoptotic cell death in human hepatoma cells: death receptor-independent activation of caspase-8 with down-regulation of Bcl-xL expression. Jpn J Cancer Res 2001;92:918-25. [PMID: 11572758 DOI: 10.1111/j.1349-7006.2001.tb01181.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
24 Sherman KE, Andersen JW, Butt AA, Umbleja T, Alston B, Koziel MJ, Peters MG, Sulkowski M, Goodman ZD, Chung RT; AIDS Clinical Trials Group A5178 Study Team. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr 2010;55:597-605. [PMID: 20921898 DOI: 10.1097/QAI.0b013e3181f6d916] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
25 Satoh M, Saito M, Tanaka K, Iwanaga S, Ali SN, Seki T, Okada S, Kohara M, Harada S, Kai C, Tsukiyama-Kohara K. Evaluation of a recombinant measles virus expressing hepatitis C virus envelope proteins by infection of human PBL-NOD/Scid/Jak3null mouse. Comp Immunol Microbiol Infect Dis 2010;33:e81-8. [PMID: 20299097 DOI: 10.1016/j.cimid.2010.02.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
26 Zandieh I, Adenwalla M, Cheong-Lee C, Ma PE, Yoshida EM. Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C. World J Gastroenterol 2006;12:4908-10. [PMID: 16937480 DOI: 10.3748/wjg.v12.i30.4908] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
27 Benvegnù L, Alberti A. Risk factors and prevention of hepatocellular carcinoma in HCV infection. Dig Dis Sci. 1996;41:49S-55S. [PMID: 9011476 DOI: 10.1007/bf02087876] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Bang CS, Song IH. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol 2017;17:46. [PMID: 28376711 DOI: 10.1186/s12876-017-0606-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
29 Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Takemura S, Yamamoto T, Ikebe T, Wakasa K. Influence of previous interferon therapy on recurrence after resection of hepatitis c virus-related hepatocellular carcinoma. Jpn J Cancer Res. 2001;92:59-66. [PMID: 11173545 DOI: 10.1111/j.1349-7006.2001.tb01048.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
30 Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics. 2006;24:661-672. [PMID: 16802842 DOI: 10.2165/00019053-200624070-00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
31 Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. World J Gastroenterol 2009;15:3462-71. [PMID: 19630099 DOI: 10.3748/wjg.15.3462] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 67] [Article Influence: 5.8] [Reference Citation Analysis]
32 Hsu CS, Huang CJ, Kao JH, Lin HH, Chao YC, Fan YC, Tsai PS. Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients. PLoS One. 2013;8:e70458. [PMID: 23894660 DOI: 10.1371/journal.pone.0070458] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
33 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 668] [Article Influence: 62.2] [Reference Citation Analysis]
34 Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, Pol S, Trinchet JC. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007;13:5648-53. [PMID: 17948941 DOI: 10.3748/wjg.v13.i42.5648] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
35 Gramenzi A, Andreone P, Fiorino S, Cammà C, Giunta M, Magalotti D, Cursaro C, Calabrese C, Arienti V, Rossi C. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut. 2001;48:843-848. [PMID: 11358906 DOI: 10.1136/gut.48.6.843] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 3.2] [Reference Citation Analysis]
36 Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 2007;13:5188-95. [PMID: 17876889 DOI: 10.3748/wjg.v13.i39.5188] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
37 Thiele M, Gluud LL, Dahl EK, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ Open 2013;3:e003265. [PMID: 23945731 DOI: 10.1136/bmjopen-2013-003265] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
38 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Reference Citation Analysis]
39 Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131-136. [PMID: 10861275 DOI: 10.1136/gut.47.1.131.] [Reference Citation Analysis]
40 Ikeda K, Arase Y, Kobayashi M, Saitoh S, Someya T, Hosaka T, Sezaki H, Akuta N, Suzuki Y, Suzuki F. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig Dis Sci. 2006;51:603-609. [PMID: 16614974 DOI: 10.1007/s10620-006-3177-0] [Cited by in Crossref: 66] [Cited by in F6Publishing: 49] [Article Influence: 4.4] [Reference Citation Analysis]
41 Scotto G, Grimaldi M. Effectiveness of leukocyte interferon-alpha treatment in patients with chronic hepatitis C not responsive to recombinant interferon. Dig Dis Sci 1998;43:2173-6. [PMID: 9790450 DOI: 10.1023/a:1026693901012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
42 Testino G, Borro P. Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. World J Hepatol. 2013;5:521-527. [PMID: 24179611 DOI: 10.4254/wjh.v5.i10.521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
43 Azzaroli F, Accogli E, Nigro G, Trere D, Giovanelli S, Miracolo A, Lodato F, Montagnani M, Tamé M, Colecchia A, Mwangemi C, Festi D, Roda E, Derenzini M, Mazzella G. Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J Gastroenterol 2004;10:3099-102. [PMID: 15457551 DOI: 10.3748/wjg.v10.i21.3099] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
44 McGivern DR, Lemon SM. Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol. 2009;4:399-415. [PMID: 18928409 DOI: 10.1146/annurev.pathol.4.110807.092202] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 5.8] [Reference Citation Analysis]
45 Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol. 2006;23:47-63. [PMID: 21326720 DOI: 10.1055/s-2006-939841] [Cited by in Crossref: 98] [Cited by in F6Publishing: 72] [Article Influence: 9.8] [Reference Citation Analysis]
46 Fabbri C, Jaboli MF, Giovanelli S, Azzaroli F, Pezzoli A, Accogli E, Liva S, Nigro G, Miracolo A, Festi D, Colecchia A, Montagnani M, Roda E, Mazzella G. Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World J Gastroenterol 2003;9:1487-90. [PMID: 12854147 DOI: 10.3748/wjg.v9.i7.1487] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
47 Solmi L, Nigro G, Roda E. Therapeutic effectiveness of echo-guided percutaneous radiofrequency ablation therapy with a LeVeen needle electrode in hepatocellular carcinoma. World J Gastroenterol 2006;12:1098-104. [PMID: 16534852 DOI: 10.3748/wjg.v12.i7.1098] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
48 Kusano H, Ogasawara S, Akiba J, Nakayama M, Ueda K, Yano H. Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo. Int J Oncol 2013;42:1897-903. [PMID: 23588838 DOI: 10.3892/ijo.2013.1904] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
49 Veldt BJ, Saracco G, Boyer N, Cammà C, Bellobuono A, Hopf U, Castillo I, Weiland O, Nevens F, Hansen BE. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004;53:1504-1508. [PMID: 15361504 DOI: 10.1136/gut.2003.038257] [Cited by in Crossref: 119] [Cited by in F6Publishing: 109] [Article Influence: 7.0] [Reference Citation Analysis]
50 Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131-136. [PMID: 10861275 DOI: 10.1136/gut.47.1.131] [Cited by in Crossref: 257] [Cited by in F6Publishing: 227] [Article Influence: 12.2] [Reference Citation Analysis]
51 Booth JC, O'Grady J, Neuberger J;  Thr Royal College of Physicians of London and the British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. Gut. 2001;49 Suppl 1:I1-21. [PMID: 11413125 DOI: 10.1136/gut.49.suppl_1.i1] [Cited by in Crossref: 86] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]